PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Expert review of key data in GI cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 31, 2022 Expired: August 30, 2023

Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Michael J. Pishvaian, MD, PhD Released: June 3, 2022

Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)

Allison Betof Warner, MD, PhD John M. Burke, MD Shaji K. Kumar, MD Christopher H. Lieu, MD Stephen V. Liu, MD Joyce O'Shaughnessy, MD Zofia Piotrowska, MD, MHS Angeles Alvarez Secord, MD, MHSc Rachna Shroff, MD Hussein Tawbi, MD, PhD Eunice S. Wang, MD Released: June 1, 2022